

il ruolo della **RICERCA** farmacologica per la **CRESCITA** e la **SALUTE** in Italia

WEDNESDAY OCTOBER 23 rd , 2013							
	Auditorium	500	Madrid	Londra	Copenhagen	Dublino	Lisbona
11.00	Registration (3P Solution desk)						
14.00	Round Table The role of drugs in health and development in Italy						
15.00	NS23 SIF - SSFA Symposium. Clinical Research in Italy: how to compete?	MS4 Innovation and technology for a competitive and sustainable health care system	NS13 Nanomedicines for cancer therapy	C2 Oral Communications: stroke and neuroinflammation		MS10 Rifaximin: new insights into the mechanisms of action (15.00-16.30)	
16.00							
17.00	Welcome Ceremony						
18.00	Plenary Lecture. From patients to industry and back: the pivotal role of academic research in the rare disease context Francesca Pasinelli						

THURSDAY OCTOBER 24 th , 2013							
	Auditorium	500	Madrid	Londra	Copenhagen	Dublino	Lisbona
8.30	C5 Oral communications: pharmacoepidemiology and pharmacovigilance	NS25 Inflammation and vulnerability to neuropsychiatric disorders: molecular mechanisms and clinical outcomes	NS16 Neurodegenerative diseases and brain injury: from cellular and molecular mechanisms to new neuroprotective strategies		C3 Oral communications: personalized medicine	C4 Oral Communications: inflammations pharmacology	C6 Oral Communications: metabolism pharmacology
9.30				L16 Omega-3 fatty acids in cardiovascular prevention: how and when?			
10.00				L3 Serelaxin: beyond the validation for AHF patient			
10.30	Coffee break						
11.00		NS1 SIF, SINPF, SIP, SITOX Symposium Neurobiological and clinical continuum between psychopathology on abuse of substances: the utility and criticism of pharmacotherapy	S1 Pharmacological innovation in oncohematology	S6 Pharmacological management of patients at high cardiovascular risk	NS5 Pharmacological, clinical and regulatory aspects of botulinum toxins	L20 Innovation in the treatment of IBD	
11.30	S5 Innovation beyond biotechnological drugs: the role of small molecules as target therapy						
12.00						S4 Adherence and economic sustainability in cardiovascular treatment	
12.30							
13.00	Lunch Novartis lunch by invitation (Istanbul room)						Assemblea Sezione di Farmacologia Clinica
14.00	Plenary Lecture. Translational research on treatment personalization in organ transplantation: from basic to clinical pharmacology and viceversa Pierre Marquet						
15.00	L1 New approaches to the administration of monoclonal antibodies	SSS1 The challenge of innovation in cardiovascular medicine between the unmet needs and the sustainability of the healthcare system	NS4 Taking rational decisions in a world of uncertainty: how to use pharmacoeconomics for reimbursement of new drugs	MS6 Alzheimer disease: today's update	MS8 Current and future state of clinical pharmacology in paediatrics	L21 New treatments of <i>Clostridium difficile</i> infections	
15.30							
16.00	MS5 The innovation of targeted therapy in the treatment of Hodgkin Lymphoma and sALCL			L15 Thermo-TRP inhibition: novel strategies to treat pain and more		MS9 Quality of equivalent (generic) drugs	
17.00	NS20 Emerging role of the endocannabinoid signaling in neuropsychiatric disorders	C17 Oral communications: pharmacology of pain	NS9 Clinical pharmacology in public health	NS18 Alzheimer disease: identification of novel targets and therapeutic tools	NS3 The need of mitochondrial pharmacology	NS7 Enzymes regulating the intra- and extra-cellular activities of purines and their antineoplastic analogues	NS22 Cardiac stem cells ten years later: future developments
19.00	Assemblea Collegio Nazionale dei Farmacologi Universitari						
19.00 21.00	Poster session A (poster area)						

LEGENDA:

ACCREDITAMENTO ECM

SENZA ACCREDITAMENTO ECM

ATTIVITÀ SIF NON ECM

FRIDAY OCTOBER 25 th , 2013							
	auditorium	500	madrid	londra	copenhagen	dublino	lisbona
8.30	C10 Oral communications: cardiovascular pharmacology 1	NS14 New research on neurodegeneration: time to translate it to clinic?	NS21 Stress as a risk factor for neuropsychiatric disorders. Cognitive and metabolic aspects		NS17 New pharmacological targets in Parkinson's disease	NS6 Insights in purinergic signalling in normal and pathological conditions of different cells and tissues	
10.00				L23 Rivaroxaban: from pharmacological characteristics to clinical evidence in atrial fibrillation and beyond			
10.30	Coffee break						
11.00	C18 Oral communications: neuropsychopharmacology	L9 New treatment solutions in antibiotic therapy: pharmaco-economic impacts evaluation	L14 Clinical, social and economic evaluation of hypoglycemia in relation to the drug treatment	L4 Preclinical development and clinical implications of mTOR inhibition in solid oncology	MS11 Before, during and after drugs: stay healthy while saving	L17 Functional bowel disorders: role of guanylate cyclase C agonists	NS10 Rare diseases: from gene to therapy: few bricks in the wall
11.30		MS3 Innovation and sustainability in a time of financial crisis	L22 Ivabradine: from pharmacological innovation to clinical benefits in heart failure	L2 Pharmacological innovation in the treatment of skin cancer: from melanoma to basal cell carcinoma		L19 New treatments for COPD: pharmacological profile of acclidinium bromide	
12.00				L7 New immunological pathways: the role of IL-17 in psoriasis	C16 Oral communications: pharmacology of the respiratory function		
12.30			L10 Clinical practice and antidepressive drugs: which differences from pharmacological point of view?	L13 Prostrate cancer: action mechanisms of new drugs		L12 Alginate containing formulations for the management of gastroesophageal reflux disease	
13.00	Lunch						
13.30	Poster session B (poster area)						
15.00	L6 The pharmacological rationale of maximization of bronchodilation in COPD	MS7 Adherence to therapy and sustainability: a new paradigm for the future	S2 Update in pharmacological therapy of T2 diabetes mellitus	L11 Analogues of insulin and relative clinical practice: which differences?	C8 Oral communications: neurogenesis	C11 Oral communications: cardiovascular pharmacology 2	
15.30	C20 Oral communications: gender medicine						
16.00	MS2 Gender medicine. Increasing appropriateness and sustainability through a sex-oriented approach	NS27 EPHAR-SIF Symposium. New paths for the treatment of alcohol addiction		L18 Role of iron in the treatment of anemia in chronic kidney disease			
17.00 - 19.00	General Assembly of the Society						

SATURDAY OCTOBER 26 th , 2013							
	auditorium	500	madrid	londra	copenhagen	dublino	lisbona
8.30	C19 Oral communications: drugs of abuse	C7 Oral communications: Alzheimer pharmacology	NS24 Brain development and synaptic organization: regulation by intellectual disability genes and immune molecules	C12 Oral communications: cardiovascular pharmacology 3	C1 Oral communications: pharmacognosy in collaboration with the pharmacognosy working group of SIF	C14 Oral communications: receptors and transduction signal mechanisms	C13 Oral communications: anticancer drugs
10.30	Coffee break (foyer)						
11.00	C15 Oral Communications: neuropharmacology	MS1 A new drug, today on the market... do we really know it? How to close the gap of drug characterization in early clinical development	NS19 Phenotyping of chronic obstructive pulmonary disease and personalized pharmacological therapy	L5 Multiple sclerosis: mechanism of action of the new oral DMDs	NS15 SIF-SIPHAR Symposium: Herbal products in research and practice: between lights and shadows	C9 Oral communications: pharmacology of the digestive apparatus	NS28 SIF/EBRA Joint Symposium: The use of animals for scientific purposes: which implications for Italian research?
11.30		NS26 SIF-AIOM Joint Symposium: pharmacogenetics as a tool for personalizing cancer treatment					
12.00							
12.30							
13.00	Awards						